key: cord-1056500-kiciow7u
authors: PALOMO, Marta; YOUSSEF, Lina; RAMOS, Alex; TORRAMADE-MOIX, Sergi; Belen MORENO-CASTAÑO, Ana; MARTINEZ-SANCHEZ, Julia; BONASTRE, Laura; PINO, Marc; GOMEZ-RAMIREZ, Pilar; MARTIN, Lidia; MATEOS, Estefania GARCIA.; SANCHEZ, Pablo; FERNANDEZ, Sara; CROVETTO, Francesca; ESCOLAR, Ginés; CARRERAS, Enric; CASTRO, Pedro; GRATACOS, Eduard; CRISPI, Fàtima; DIAZ-RICART, Maribel
title: Differences and similarities in endothelial and angiogenic profiles of preeclampsia and COVID-19 in pregnancy
date: 2022-03-26
journal: Am J Obstet Gynecol
DOI: 10.1016/j.ajog.2022.03.048
sha: e3b1f99f6ca4f6205680ff8ec9b3b22bb718fed0
doc_id: 1056500
cord_uid: kiciow7u

Background COVID-19 presents a spectrum of signs and symptoms in pregnant women that might resemble preeclampsia. Differentiation between severe COVID-19 and preeclampsia is difficult in some cases. Objective To study biomarkers of endothelial damage, coagulation, innate immune response and angiogenesis in preeclampsia and COVID-19 in pregnancy in addition to in vitro alterations in endothelial cells exposed to sera from pregnant women with preeclampsia and COVID-19. Methods Plasma and sera samples were obtained from pregnant women with COVID-19 infection classified into mild (n=10) or severe (n=9) in addition to normotensive pregnancies as controls (n=10) and patients with preeclampsia (n=13). A panel of plasmatic biomarkers was assessed including vascular cell adhesion molecule-1 (VCAM-1), soluble TNF-receptor I (sTNFRI), heparan sulfate (HS), von Willebrand factor (VWF) antigen, activity and multimeric pattern, α2-antiplasmin (α2AP), C5b9, neutrophil extracellular traps (NETS), placental growth factor (PlGF), fms-like tyrosine kinase-1 (sFlt-1) and angiopoietin 2 (Ang2). Additionally, microvascular endothelial cells were exposed patient’s serum, and changes in the cell expression of intercellular adhesion molecule 1 (ICAM-1) on cell membrane and VWF release to the extracellular matrix were evaluated through immunofluorescence. Changes in inflammation cell signaling pathways were also assessed by of P38MAPK phosphorylation. Statistical analysis included univariate and multivariate methods. Results Biomarker profiles in mild COVID-19 were similar to controls. Both preeclampsia and severe COVID-19 showed significant alterations in the majority of circulating biomarkers with distinctive profiles. While severe COVID-19 exhibited higher concentrations of VCAM-1, sTNFR-I, HS, VWF antigen and NETS with a significant reduction of PlGF as compared to controls; preeclampsia presented a marked increase in VCAM-1, sTNFR-I (significantly increased compared to controls and to severe COVID-19) with a striking reduction in VWF antigen, VWF activity and α2AP. As expected, reduced PlGF, increased sFlt-1 and Ang2 and a very high sFlt-1/PlGF ratio were also observed in preeclampsia. In addition, a significant increase in C5b9 and NETS was also detected in preeclampsia compared to controls. The principal component analysis demonstrated a clear separation between preeclampsia and the rest of groups (first and second components explained 42.2% and 13.5% of the variance), mainly differentiated by variables related to VWF, sTNFRI, HS and sFlt-1. VWF multimeric analysis revealed the absence of VWF high-molecular-weight multimers in preeclampsia (similar profile to von Willebrand disease type 2A) whereas in healthy pregnancies and COVID-19 patients, VWF multimeric pattern was normal. Sera from both preeclampsia and severe COVID-19 patients induced an overexpression of ICAM-1 and VWF in endothelial cells in culture compared to controls. However, the effect of preeclampsia was less pronounced than the one triggered by severe COVID-19. Immunoblots of lysates from endothelial cells exposed to mild and severe COVID-19, and preeclampsia sera showed an increase in p38MAPK phosphorylation. Severe COVID-19 and preeclampsia were statistically different from controls, suggesting that both severe COVID-19 and preeclampsia sera can activate inflammatory signaling pathways. Conclusion While similar in vitro endothelial dysfunction, preeclampsia and severe COVID-19 exhibit distinctive profiles of circulating biomarkers related to endothelial damage, coagulopathy and angiogenic imbalance that could aid in the differential diagnosis of these entities.

Spain. All funders had no role in the study design, data collection, data analysis, data 51 interpretation and writing the manuscript. 52 diagnosis of these disorders during pregnancy. 79

Preeclampsia is a pregnancy complication and a leading cause of maternal and perinatal morbi-130 mortality and iatrogenic prematurity 1-3 . Although its etiology is not completely understood 4,5 , 131 it is accepted that this condition relies on placental insufficiency and maternal cardiovascular 132 maladaptation underlined by angiogenic imbalance, endothelial dysfunction, coagulopathy and 133 complement dysregulation 6-8 , which lead clinically to hypertension and proteinuria that can 134 progress to multi-organ dysfunction during pregnancy. The multifactorial nature of 135 preeclampsia explains a variable clinical/laboratory presentation, mainly determined by 136 gestational age at onset: early vs late. 137

Clinical and analytical data from patients infected by severe acute respiratory syndrome 138 coronavirus-2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), suggest 139 that endothelial dysfunction plays an important role in the pathophysiology of this condition 9-140 12 involving extrapulmonary manifestations of COVID-19 like hypertension, kidney disease, 141 thrombocytopenia, and liver injury. Some of these clinical features overlap with those observed 142 in preeclampsia. In addition, an increased incidence of preeclampsia has been reported in 143 association with COVID-19 13-15 . Despite their clinical resemblance, the mechanisms 144 underlying endothelial dysfunction might differ between COVID-19 and preeclampsia. 145

Understanding endothelial and angiogenic profiles could enlighten the pathophysiological basis 146 of these two entities. 147

The endothelium is a monolayer of cells that lines the interior of blood vessels acting as a 148 protective layer between circulating blood and other tissues. The endothelium is crucial for the 149 regulation of vascular homeostasis, coagulation cascade, immune response and angiogenesis. 150

Circulating biomarkers related to endothelial activation and loss of barrier integrity seem to be 151 associated to disease severity in COVID-19 12, 16 . Inflammatory effects on these damaged 152 endothelial cells activates the innate immune response and induces a hypercoagulable state with 153 impaired fibrinolysis and angiogenic imbalance 17, 18 . On the other hand, angiogenesis 154 dysregulation has emerged as one of the main pathophysiological features in the development 155 of preeclampsia 19, 20 . Finally, in vitro studies enabled us to describe the endothelial cell 156 proinflammatory and thrombogenic response in COVID-19 [21] [22] [23] . 157

The aim of the present study was to comprehensively investigate the endothelial and angiogenic 158 profiles in preeclampsia and SARS-CoV-2 infection in pregnancy using circulating biomarkers 159 and in vitro studies. 160

Pregnant women with laboratory confirmed SARS-CoV-2 infection were selected from a large 163 multicenter prospective population-based cohort study conducted from March 15 to May 31, 164 2020, in Barcelona, Spain including consecutive cases detected during the study period 24 . 165 SARS-CoV-2 infection was confirmed by a positive real time polymerase chain reaction (RT-166 PCR) on nasopharyngeal swab or a positive serological result. SARS-CoV-2 positive 167 pregnancies were subdivided into mild (n=9) and severe disease (n=8) according to the presence 168 of pneumonia or coexistence of fever, dry cough and dyspnea. In addition, we also included 169 SARS-CoV-2 negative pregnant women including preeclampsia (n=13) and normotensive 170 pregnancies as controls (n=10) who were matched to COVID-19 cases by gestational age at 171 blood sampling. preeclampsia was defined as high blood pressure (systolic blood pressure ≥ 172 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg on two occasions, at least four hours 173 apart) developed after 20 weeks of gestation with proteinuria (≥ 300 mg/24 h or 174 protein/creatinine ratio ≥ 0.3), thrombocytopenia (platelet count < 100 x 10 9 /l, renal 175 insufficiency (serum creatinine concentrations > 1.1 mg/dl), impaired liver function (elevated 176 blood concentrations of liver transaminases to twice normal concentration), pulmonary edema 177 or a new-onset headache unresponsive to medication and not accounted for by alternative 178 diagnoses or visual symptoms 25 . Early-onset preeclampsia was defined by gestational age at 179 delivery before 34 weeks of gestation 26 . Baseline and perinatal data were obtained by interviews 180 and from electronic medical records. Gestational age was calculated based on the crown-rump 181 length at first trimester ultrasound 27 . Birthweight centiles were assigned according to local 182 standards 28 . Pregnancies with chromosomal/structural anomalies or intrauterine infection were 183 excluded. Endothelial and angiogenic profiles were studied in all participants by analyzing exposed to patient's sera. Details of the laboratory methodology used is detailed below and in 186 the Supplementary material. 187

This study was approved by the ethics committee of Hospital Clinic (HCB/2020/0401) and 188 conformed to the ethical guidelines of the Helsinki Declaration. All participants provided 189 informed written consent before sample collection. 190

Peripheral maternal blood was obtained by venipuncture within 24-48 hours of the onset of 192 symptoms and before starting any treatment. Plasma and sera samples were obtained by 193 centrifugation of blood anticoagulated with EDTA and by incubation for 30 min at room 194 temperature to allow clotting and subsequently centrifuged at 1500×g for 10 min at 4 °C to 195 separate the serum from clots, respectively. All samples were aliquoted and stored at -80°C 196 until used. 197 

Baseline characteristics of the study populations are summarized in Table 1 . Study groups were 246 mainly similar in terms of maternal and perinatal characteristics. However, preeclamptic 247 patients had higher rates of Asian ethnicity and a tendency to younger age. Chronic 248 hypertension was present in three preeclamptic patients and systemic lupus erythematosus in 249 one control. None of the patients included in this study had pregestational diabetes or previous 250 respiratory disorders. All the pregnancies complicated by preeclampsia were proteinuric, four 251 were early-onset cases that were treated with corticosteroids for fetal lung maturity and five 252 preeclamptic patients had preeclampsia with severe features that was treated with magnesium 253 sulfate. Preeclamptic patients showed an earlier gestational age at delivery with a trend to higher 254 rates of small-for-gestational-age fetus and admissions to neonatal intensive care unit. Three 255 cases of preeclampsia were complicated by peripartum hemorrhage. Severe COVID-19 cases 256 were all detected by RT-PCR. Among the mild cases, two were detected by RT-PCR and the 257 rest by positive serology. Since this study has been conducted at the beginning of the pandemic, 258 convalescent subjects should have been infected during the four weeks preceding the blood 259 analysis. Two cases of mild COVID-19 had hypertension and one of them had associated 260 proteinuria. None of the COVID-19 patients (mild or severe) had thrombocytopenia, elevated 261 liver enzymes or elevated creatinine. All COVID-19 cases were followed up to 40 days 262 postpartum to exclude the diagnosis of evolving preeclampsia. The diagnosis of atypical 263 preeclampsia in COVID-19 cases was excluded as none of them presented signs of placental 264 insufficiency nor abnormal sFlt1/PlGF ratio (according to our institutional protocol for the 265 differential diagnosis of hypertensive disorders in pregnancy). Severe COVID-19 cases were 266 not critically ill (no mortality and only one case required invasive mechanical ventilation). Six 267 were additionally treated with hydroxychloroquine and azithromycin and one of these three has 269 been also given lopinavir / ritonavir and corticosteroids. As mentioned earlier, maternal blood 270 samples were obtained before starting any treatment. Gestational age at sampling was similar 271 between the study groups at median (interquartile range) of 40.2 (38.9 -41) weeks in controls, Results on soluble biomarkers in the study populations are displayed in Figure 1 and Table S1 . Table S2) , with much 306 remarkable changes in early-onset cases. In contrast, C5b9 and NETS were more altered in late-307 onset preeclampsia. 308

Endothelial cells incubation with sera from mild and severe COVID-19 patients induced a 311 significant overexpression of ICAM-1 and VWF compared with controls ( Figure 4) . Cells 312 exposed to preeclampsia sera showed also significantly increased ICAM-1 and VWF 313 expression although preeclampsia effect was less pronounced than the one caused by severe 314 COVID-19 (p<0.05). 315

Immunoblots of lysates from endothelial cells exposed to mild and severe COVID-19, and 316 preeclampsia sera showed an increase in p38MAPK phosphorylation. Severe COVID-19 and 317 preeclampsia were statistically different from controls ( Figure 5) , suggesting that both severe 318 COVID-19 and preeclampsia sera can activate inflammatory signaling pathways. 

Interestingly, the most remarkable differences between preeclampsia and COVID-19 were 351 observed in VWF concentrations and activity. Our data in COVID-19 pregnancies are 352 consistent with the previously described positive correlation of VWF with disease severity 12 . 353

Conversely, in preeclampsia, we observed a striking decrease in VWF levels contrary to the 354 increase reported formerly in the literature 36 . Interestingly, these changes were more 355 pronounced in more severe early-onset cases. A potential explanation to this observation is 356 acute VWF consumption due to endothelial cell exhaustion 37 in preeclampsia, as indeed, the in 357 vitro exposure of endothelial cells to preeclampsia sera resulted in a relevant increase in VWF 358 release. Other potential explanations could be bleeding or drug interaction (with corticosteroids 359 given to ensure lung maturity). Moreover, our results suggest a qualitative VWF defect in 360 preeclampsia manifested by low VWF:GPIbM/VWF:Ag ratio and confirmed by the multimeric 361 analysis of VWF. Since ADAMTS-13 activity was similar in preeclampsia and the other study 362 groups, the loss of high-molecular-weight multimers might be due to the lysis by other proteases 363 such as plasmin. In fact, the degradation of VWF by plasmin has been described in 364 hyperfibrinolytic states 38 and preeclampsia is known to be a hypercoagulable and seem to be highly specific to differentiate preeclampsia from severe COVID-19 in pregnancy. 433 pathways in preeclampsia and COVID-19 in pregnancy. We also identify circulating 435 biomarkers that may be useful in the differential diagnosis of preeclampsia and SARS-CoV-2 436 infection in pregnancy. Given the difficulty of clinically differentiate some cases of 437 preeclampsia and COVID-19, a panel of circulating biomarkers for the differential diagnosis 438 could be of most help to optimize patient's management. Finally, this study also opens 439 opportunities for new therapeutic targets that could improve the underlying endothelial damage 440 observed in these entities. 441

We thank all the patients that agreed to participate in the present study. We would like to thank 443 

The Global Impact of Pre-eclampsia and Eclampsia

Maternal Mortality From Preeclampsia/Eclampsia

Pre-eclampsia

Preeclampsia and eclampsia: the conceptual evolution 455 of a syndrome

The etiology of preeclampsia

The placenta and preeclampsia: villain or 460 victim?

Imbalances in circulating angiogenic factors in the 463 pathophysiology of preeclampsia and related disorders

Complement activation and regulation in preeclampsia and 466 hemolysis, elevated liver enzymes, and low platelet count syndrome

Pathogenesis of Organ Injury in Severe COVID-19

Endotheliopathy Is Induced by Plasma From 472

Critically Ill Patients and Associated With Organ Failure in Severe COVID-19

SARS-CoV-2 and the subsequent development of 484 preeclampsia and preterm birth: evidence of a dose-response relationship supporting 485 causality

SARS-CoV-2 related myocardial injury might explain 488 the predisposition to preeclampsia with maternal SARS-CoV-2 infection

Elevated expression of serum endothelial cell adhesion 491 molecules in COVID-19 patients

Endothelial cell infection and endotheliitis in

Angiogenic factors in preeclampsia: From diagnosis to therapy

Circulating Angiogenic Factors and the Risk of

The course of angiogenic factors in early-vs. late-591 onset preeclampsia and HELLP syndrome

Pre-eclampsia-like syndrome induced by 594 severe COVID-19: a prospective observational study

Endothelial-dependent 597 mechanisms of leukocyte recruitment to the vascular wall

Respiratory Syndrome Coronavirus Inhibits Cellular Protein Synthesis and Activates 601 p38 Mitogen-Activated Protein Kinase

606 analysis was performed to confirm the qualitative defects of this protein suggested by the low 644 VWF:Ag/VWF:GPIb detected in PE patients. A normalized 1.2% multimer gel (A) and 645 densitometry (B) of plasma VWF multimers from normal control (C)

Sample 651 identification is followed by the dilution used to resolve VWF multimeric pattern. 652 performed by exposing resting endothelial cells to the sera under study. In the present study, 668 activation of p38 MAPK (a kinase with a key role in inflammatory cellular responses to 669 injurious stress

Immunoblot 671 image shows phosphorylated p38 MAPK and B-actin, and the boxplots represent the relative 672 quantification of p38 MAPK / B-actin

ADAMTS-677 13): is primarily synthesized in the liver, and its main function is to cleave von 678 Willebrand factor (VWF) anchored on the endothelial surface, in circulation, and at the 679 sites of vascular injury

Ang2): is produced by endothelial cells and acts as an autocrine 682 regulator mediating vascular destabilization and regulating vascular homeostasis

• α2-antiplasmin (α2AP): is a serine protease inhibitor (serpin) responsible for

• Endothelium: composed by endothelial cells plays an important role in inflammation by 688 regulating vascular permeability for macromolecules and leukocytes, vascular tone and 689 hemostasis, and by binding and producing and inflammatory mediators such as 690 cytokines

Ex vivo approach: to quantify the degree of endothelial activation is of interest when 693 evaluating inflammation. Due to the localization of this type of cells

which acts as an antagonist of vascular endothelial growth 700 factor (VEGF) and placental growth factor (PlGF) and is upregulated in preeclampsia

• sFlt-1/PIGF ratio: an imbalance in these two biomarkers levels has been reported to be 703 involved in preeclampsia pathogenesis. An elevated sFlt-1/PIGF seems to be highly 704 predictive of preeclampsia

HS): is glycosaminoglycan from endothelial glycocalyx used by viral 707 pathogens such as SARS-CoV-2 for the initial interaction with host cells

In vitro approach: consists in a well characterized in vitro model of endothelial 710 dysfunction, in which endothelial cells in culture are exposed to patient's sera in order 711 to assess its capacity to modulate the endothelial phenotype. This analysis is performed 712 through the quantification of changes in inflammatory and thrombogenicity markers 713 together with the activation of certain intracellular signaling pathways

• Intercellular adhesion molecule-1 (ICAM-1): adhesion molecule that is upregulated 716 during endothelial activation and mediates lymphocyte binding. This molecule is not 717 only released from endothelium, but also from lymphocytes, monocytes and 718 eosinophils

• Neutrophil extracellular traps (NETS): are extracellular webs of chromatin, 721 microbicidal proteins, and oxidant enzymes that are released by neutrophils to fight 722 against infections and that

Placental growth factor (PlGF): is a member of the vascular endothelial growth factor 726 (VEGF) family and is predominantly expressed in the placenta

PAI): is a member of the serine protease inhibitor 731 (serpin) superfamily and constitutes a central molecule linking pathogenesis and 732 progression of thrombotic vascular events

Principal component analysis: is a statistical method that aims to reduce the 735 dimensionality of large data sets by transforming them into a smaller ones

• p38 mitogen-activated protein kinase (P38MAPK): plays a pivotal role mediating 740 cellular responses to injurious stress and immune signaling partly through the activation 741 of gene expression

C5b9): is also known as soluble membrane attack complex 744 and constitutes a marker of complement activation. This molecule creates a 745 transmembrane channel on the surface of targeted cell that leads to cell lysis and death

TNFα), a proinflammatory cytokine that plays a central role in inflammation, which 749 act as physiological attenuator of TNFα activity

TM): is a thrombin receptor on endothelial cells that is involved in 752 promoting activation of the anticoagulant protein C pathway during blood coagulation

Vascular Cell Adhesion Molecule -1 (VCAM-1): adhesion molecule that is upregulated 755 during endothelial activation and mediates lymphocyte binding

VWF): a multimeric blood protein primarily synthesized, stored 759 and secreted by endothelial cells

Factor multimeric analysis: is a method carried out by electrophoresis 764 of plasma samples using non-reducing agarose gels in the presence of different 765 concentrations of sodium dodecyl sulphate. This analysis aims to identify qualitative 766 defects of this protein and is usually performed after functional and immunological 767 VWF assays indicate a potential abnormality